RLMD

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for central nervous system (CNS) and metabolic disorders. The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of CNS diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Its lead product candidate, esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications. Sepranolone is its phase IIb ready neurosteroid developed for the potential treatment of Tourette syndrome and other compulsive disorders.

Wall Street analysts forecast RLMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RLMD is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Relmada Therapeutics Inc revenue for the last quarter amounts to -10.33M USD, decreased -55.12 % YoY.

Relmada Therapeutics Inc. EPS for the last quarter amounts to -6721856.00 USD, decreased -59.64 % YoY.

Relmada Therapeutics Inc (RLMD) has 17 emplpoyees as of December 15 2025.

Today RLMD has the market capitalization of 297.73M USD.